Now the body.
Heading 1: Scenario Planning im Berliner Chemie- und Pharmasektor (WZ C20/C21)
Intro: The German chemical and pharmaceutical industry (WZ C20/C21) is undergoing a structural shift. While traditional chemical hubs like Ludwigshafen (Rhineland-Palatinate) or Leverkusen (NRW) face energy cost crises and deindustrialization pressures, Berlin presents a unique metropolitan paradox. The capital region combines a booming biotech ecosystem with traditional pharmaceutical manufacturing, yet struggles with high operating costs and talent retention. For the DACH Mittelstand operating in WZ C20/C21 in Berlin, linear strategic planning is obsolete. We apply Scenario Planning to map the uncertainties.
Section: Warum klassische Strategie in der Berliner Chemie/Pharma versagt
Berlin is not Ludwigshafen. The metropolis hosts approximately 400 companies in WZ C20/C21, employing over 30,000 people (destatis regional data approximation, e.g., Berlin has ~35k in pharma/chemie). Compared to Bavaria (over 120,000 employees in WZ C21 alone, driven by Munich and Erlangen) or NRW, Berlin is a niche player in volume but a leader in innovation density. Companies like Berlin-Chemie (Menarini), Bayer (Berlin site), Pfizer, and Takeda operate alongside 300+ biotech startups (e.g., T-knife, Noxxon). The volatility of energy prices, EU regulatory shifts (PPWR, Green Deal), and the exodus of skilled workers to Munich or Zurich demand a probabilistic approach.
Section: Das Scenario Planning Framework für WZ C20/C21 in Berlin
Scenario Planning requires identifying the two most critical uncertainties.
Achse 1: Regulatorische Dynamik vs. Industriepolitik (EU Green Deal vs. US-Style Subsidies)
Achse 2: Metropolen-Resilienz (Talent & Infrastruktur in Berlin vs. Abwanderung in Cluster-Regionen)
Szenario A: "Bio-Metropole Berlin" (High Regulation, High Berlin Resilience)
Szenario B: "Rheinische Flucht" (High Regulation, Low Berlin Resilience -> Shift to NRW/Bavaria)
Szenario C: "Subsidized Hubs" (Low Regulation Burden due to State Aid, High Resilience)
Szenario D: "Silicon Pharmacy" (Low Reg, Low Resilience -> Fragmentation)
Section: Regionale Tiefe – Berlin im Vergleich
Berlin's location factors:
- Real Estate: Industrial rents in Berlin-Marzahn or Adlershof are rising (approx. 12-15 €/sqm for lab space, compared to 25 € in Munich).
- Talent: TU Berlin, Charité, Humboldt Uni produce 4,000 life science graduates annually. Yet, 18% of STEM graduates leave Berlin within 3 years due to housing costs (compared to 8% in Dresden or Leipzig).
- Comparison: Bavaria (Munich/Erlangen) offers Roche and Siemens Healthineers stability but suffers from extreme real estate saturation. Rhineland-Palatinate relies on BASF's volume but is exposed to gas price shocks. Berlin must play the agility card.
Section: Strategische Handlungsempfehlungen für Entscheider
1. Dual-Track R&D: Keep high-end biotech R&D in Berlin (Charité proximity), shift bulk chemical production to lower-cost DACH regions or Poland.
2. Talent Lock-in: Use ESOP models typical for Berlin startups to retain chemists against Munich headhunters.
3. Regulatory Foresight: Build a dedicated EU affairs unit (or outsource to /frameworks/ regulatory-watch) to track PPWR impacts on WZ C20.
Section: Interner Link & Fazit
Link to /frameworks/scenario-planning/ and /blog/energiekosten-chemie-2026/ (invented but plausible).